• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Y-Mabs Therapeutics Inc (NQ: YMAB )

    15.55 -0.14 (-0.89%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Y-Mabs Therapeutics Inc

    < Previous 1 2 3 4 5 6 Next >
    Examining the Future: Y-mAbs Therapeutics's Earnings Outlook
    Via Benzinga
    Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
    Via Benzinga
    Navigating 8 Analyst Ratings For Y-mAbs Therapeutics
    Via Benzinga
    Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts
    Via Benzinga
    Why Y-mAbs Therapeutics Stock Got Mashed on Monday
    The company didn't quite meet expectations for either trailing results or full-year guidance. 
    Via The Motley Fool
    YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024
    YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
    Via Benzinga
    Earnings Scheduled For February 29, 2024
    Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
    Via Benzinga
    Earnings Outlook For Y-mAbs Therapeutics
    Via Benzinga
    Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB
    From Pomerantz LLP
    Via GlobeNewswire
    MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
    Via Benzinga
    YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
    YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Earnings Preview For Y-mAbs Therapeutics
    Via Benzinga
    4 Analysts Have This to Say About Y-mAbs Therapeutics
    Via Benzinga
    Analyst Expectations for Y-mAbs Therapeutics's Future
    Via Benzinga
    Where Y-mAbs Therapeutics Stands With Analysts
    Via Benzinga
    Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. 
    Via Benzinga
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To Know
    Via Benzinga
    Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance. 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
    In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. 
    Via Investor's Business Daily
    Micro Marvel - Y-Mabs Therapeutics
    Wall Street projected revenue will grow 26.00% this year and another 18.80% next year. Earnings are estimated to increase 68.90% this year but decrease 8.80% next year. 
    Via Talk Markets
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility
    Wedbush has upgraded Y-mAbs Therapeutics Inc (NASDAQ: YMAB)to Outperform from Neutral, with a  
    Via Benzinga
    Earnings Scheduled For November 13, 2023
    Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
    Via Benzinga
    Earnings Scheduled For August 10, 2023
    Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.